Aclaris Therapeutics Forecast and Stock Analysis
Technical ACRS stock analysis for March 18, 2019.
| Shorts | n/a |
| Cash | n/a |
| Loans | n/a |
| Beta | 1.24 |
| ROA | -53.53 |
Aclaris Therapeutics gained 20.43% in the last trading day, rising from $5.63 to $6.78 The price has fallen in 6 of the last 10 days and is down by -0.44% for this period. Volume has increased in the last day along with the price, which is a positive technical sign, and, in total, 0.59 million more shares were traded than the day before. In total, 1.71 million shares bought and sold for approximately $11.60 million.
Close price at the end of the last trading day (Monday, 18th Mar 2019) of the ACRS stock was $6.78. This is 20.43% more than the trading day before Friday, 15th Mar 2019.
During day the stock fluctuated 33.87% from a day low at $5.61 to a day high of $7.51.
30 day high of the ACRS stock price was $7.51 and low was $5.49.
90 day high was $8.19 and low was $5.49.
52 week high for the Aclaris Therapeutics - $21.97 and low - $5.49.
Trend
Aclaris Therapeutics lies the upper part of a very wide and falling trend in the short term, and this will normally pose a very good selling opportunity for the short-term trader as reaction back towards the lower part of the trend can be expected. A break up at the top trend line at $7.04 will firstly indicate a slower falling rate, but may be the first sign of a trend shift. Given the current short-term trend, the stock is expected to fall -13.82% during the next 3 months and, with 90% probability hold a price between $4.61 and $6.07 at the end of this period.
Signals
Only positive signals in the chart today. Aclaris Therapeutics holds buy signals from both short- and long-term moving averages, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections down there will be some support from the lines at $5.91 and $6.59. A break down below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Friday March 15, 2019, which indicates further gains until a new top pivot has been found. Volume is rising along with the price. This is considered to be a good technical signal.
Access today's Top 5 Golden Star Companies
Relative Strength Index (RSI)
RSI14 is 54 and the stock is currently not being overbought or oversold
Support & Resistance
Aclaris Therapeutics finds support from accumulated volume at $6.46.
Risk
This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $1.90 between high and low, or 33.87%. For the last week, the stock has had a daily average volatility of 11.79%.
Our recommended stoploss: $6.45 (-4.82%) (This stock has high daily movements and this gives high risk. There is a buy signal from pivot bottom found 1 days ago.)
Overall risk:
Very Low Low Medium High Very High
Evaluation: Buy Candidate
Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for this stock to perform well in the short-term. We have upgraded our recommendation for this stock since last evaluation from a Strong Sell Candidate to a Buy Candidate.
